APR developed and patented the innovative oral drug delivery system (Immediate Release Technology/IRT) used in a range of oral products including diclofenac potassium (50 mg).
In particular, Diclofenac (50 mg) powder for oral solution, thanks to its very quick/fast absorption and onset of action (15 min) has been shown to be valuable in the management of migraine (recurring headaches often associated with visual, auditory or gastrointestinal disturbances) with efficacy comparable to that of the triptans - the current golden standard in the treatment of migraine/cluster headaches.